MedTrace Logo

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

NCT06157060 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 255

Last updated 2026-03-20

No results posted yet for this study

Summary

This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.

Conditions

  • Hepatocellular Carcinoma Resectable

Interventions

DIAGNOSTIC_TEST

circulating tumor DNA

blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Mingxin Pan · Southern Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2026-11-20
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06157060 on ClinicalTrials.gov